Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Indian J Cancer ; 57(Supplement): S1-S5, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32167063

ABSTRACT

Head and neck cancers (HNCs) are malignant tumors of the upper aerodigestive tract and are the sixth most common cancer worldwide. In India, around 30-40% of all cancers are HNCs. Even though there are global guidelines or recommendations for the management of HNCs, these may not be appropriate for Indian scenarios. In an effort to discuss current practices, latest developments and to come to a consensus to recommend management strategies for different anatomical subsites of HNCs for Indian patients, a group of experts (medical, surgical and radiation oncologists and dentists) was formed. A review of literature from medical databases was conducted to provide the best possible evidence base, which was reviewed by experts during a consensus group meeting (January, 2019) to provide recommendations.


Subject(s)
Head and Neck Neoplasms/therapy , Medical Oncology/standards , Squamous Cell Carcinoma of Head and Neck/therapy , Combined Modality Therapy/standards , Consensus , Head and Neck Neoplasms/diagnosis , Humans , India , Medical Oncology/methods , Patient Care Team/standards , Practice Guidelines as Topic , Practice Patterns, Physicians' , Prognosis , Squamous Cell Carcinoma of Head and Neck/diagnosis
8.
Neurol India ; 66(6): 1726-1731, 2018.
Article in English | MEDLINE | ID: mdl-30504574

ABSTRACT

BACKGROUND: The plethora of biomarkers available for the diagnosis and prognostication of gliomas has refined the classification of gliomas. The new World Health Organization (WHO) 2016 classification integrates the phenotypic and genotyping features for a more robust diagnosis. MATERIALS AND METHODS: Fifty gliomas with oligodendroglial morphology according to the WHO 2007 classification were analyzed for isocitrate dehydrogenase 1 and 2 (IDH1/2) mutations by polymerase chain reaction, 1p/19q status by fluorescent in situ hybridization (FISH), and IDH1 and X-linked alpha-thalassemia retardation (ATRX) expression by immunohistochemistry. Tumors were reclassified into oligodendrogliomas, astrocytomas, and glioblastomas (GBMs) according to the new "integrated" diagnostic approach. RESULTS: 30% of previously diagnosed oligodendrogliomas and almost 90% of oligoastrocytomas were reclassified as astrocytomas. Twenty gliomas showed 1p/19q co-deletion, while 18 gliomas showed polysomy of chromosome 1/19. Polysomy of chromosome 1/19 was significantly associated with astrocytic tumors (P ≤ 0.001). Loss of ATRX expression was seen in 20 of 23 WHO grade II/III astrocytomas and 3 of 7 GBMs. All WHO grade II and III gliomas in our cohort showed IDH1/2 mutations. Moreover, 4 of 7 GBMs showed the wild-type IDH1/2 mutation, and 2 of 3 GBMs which showed IDH1/2 mutations were secondary GBMs. There was no significant difference in progression-free and overall survival between WHO grade II and III gliomas, possibly because all these tumors showed IDH1/2 mutations. In multivariate analysis, only the WHO grade (grade IV versus II and III combined) was significantly associated with increased risk of recurrence and death (P = 0.016 and 0.02). CONCLUSION: The new integrated diagnosis provides a more meaningful classification, removing the considerable subjectivity that existed previously.


Subject(s)
Astrocytoma/diagnosis , Brain Neoplasms/diagnosis , Glioblastoma/diagnosis , Glioma/diagnosis , Oligodendroglia/metabolism , Oligodendroglioma/diagnosis , Adolescent , Adult , Astrocytoma/metabolism , Astrocytoma/pathology , Biomarkers, Tumor/metabolism , Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Female , Glioblastoma/metabolism , Glioblastoma/pathology , Glioma/metabolism , Glioma/pathology , Humans , Isocitrate Dehydrogenase/metabolism , Male , Middle Aged , Oligodendroglia/pathology , Oligodendroglioma/metabolism , Oligodendroglioma/pathology , Prognosis , X-linked Nuclear Protein/metabolism , Young Adult
9.
J Clin Diagn Res ; 10(7): XC01-XC04, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27630935

ABSTRACT

INTRODUCTION: Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear. AIM: The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy. MATERIALS AND METHODS: Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method. RESULTS: The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly. CONCLUSION: We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion.

SELECTION OF CITATIONS
SEARCH DETAIL
...